Title:
GUIDED COMBINATIONAL THERAPEUTIC ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2018/226985
Kind Code:
A3
Abstract:
The present invention relates to novel multi-specific antibodies comprising fine tuned combination of low affinity single binding domain fragments to selectively targetdouble targets on cancer cell, and use thereof for therapy, such as for guided immunotherapy.
Inventors:
YONGJUN GUAN (US)
Application Number:
PCT/US2018/036497
Publication Date:
January 17, 2019
Filing Date:
June 07, 2018
Export Citation:
Assignee:
ANTIBODY BIOPHARM INC (US)
YONGJUN GUAN (US)
YONGJUN GUAN (US)
International Classes:
C12P21/00; A61K38/00; C07K14/00
Foreign References:
| US20160122432A1 | 2016-05-05 | |||
| US20130165389A1 | 2013-06-27 | |||
| US20070292936A1 | 2007-12-20 |
Other References:
CASTOLDI, R ET AL.: "Molecular Characterization of Novel Trispecific ErbB-cMet-IGF1R Antibodies and Their Antigen-Binding Properties", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 25, no. 10, 29 August 2012 (2012-08-29), pages 551 - 559, XP055041659
RUDNICK, SI ET AL.: "Affinity and Avidity in Antibody-Based Tumor Targeting", CANCER BIOTHERAPY - AND RADIOPHARMACEUTICALS, vol. 24, no. 2, 2009, XP055069540
RUDNICK, SI ET AL.: "Affinity and Avidity in Antibody-Based Tumor Targeting", CANCER BIOTHERAPY - AND RADIOPHARMACEUTICALS, vol. 24, no. 2, 2009, XP055069540
Attorney, Agent or Firm:
XI, Chen (US)
Download PDF: